Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 19/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10124358 | 1.00 | PIK3CD (0.51) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL10124377 | 0.93 | PIK3CD (0.55) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL10124375 | 0.90 | PIK3CB (0.51) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL10124376 | 0.90 | PIK3CB (0.51) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL16308241 | 0.89 | PIK3CB (0.55) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL10124356 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL10124355 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL10124443 | 0.88 | PIK3CD (0.55) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL10124446 | 0.88 | PIK3CD (0.55) | PIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL16308113 | 0.88 | PIK3CB (0.55) | PIK3CDPIK3CBPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PIK3CD 7/4885PIK3CB 13/4885PIK3CA 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.